Search

621 Result(s)
Sort by

Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
S&P Animal Health Partnering Oct 2023

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
The Goals to Improve Living with GPP

The Goals to Improve Living with GPP

An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
The GPP Forum Report

The GPP Forum Report

The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Data Science

Data Science

Revolutionizing research and development with data driven insights